Johns Hopkins researchers identified a new target for treating Alzheimer’s disease by focusing on a protein that produces ...

6 min read | UniQure secured a Type A FDA meeting, a high-priority discussion for urgent issues. Within 30 days, both sides will discuss what kind of data package might support the advancement of ...

Researchers have identified a brain protein whose absence leads to memory loss and Alzheimer’s-like damage in mice.

Qure N.V. (NASDAQ:QURE) shares are popping on Friday after the company said the FDA will review the data package for AMT‑130, ...

A protein that produces hydrogen sulfide may be a new therapeutic target, as its deficiency is linked to cognitive deficits ...

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...

Shares of UniQure were higher after the gene therapy company said it had scheduled a Type A meeting with the Food and Drug Administration to discuss a Biologics License Application for the company's ...

Qure N.V. (NASDAQ:QURE) surged around 15% in early trading on Friday after the company said it has secured a Type A meeting ...

A large genetic study shows that many people carry DNA sequences that slowly expand as they get older. Common genetic ...

The Company expects to provide a regulatory update after the receipt of official meeting minutes.

NEW YORK – Sarepta Therapeutics on Wednesday said it submitted an application to regulators in New Zealand, seeking to begin a first-in-human trial of SRP-1005, the siRNA drug it's developing for ...

Loqus23 Therapeutics Ltd. has nominated LQT-23, a first-in-class allosteric oral small-molecule inhibitor of MSH3/MutSβ, as a development candidate for Huntington’s disease.